D9975135.101101

PTO/Se/05 (08-00) roved for use through 10/31/2002. OMB 0651-0032 mark Office; U.S. DEPARTMENT OF COMMERCE on unless it displays a valid OMB control number. 113PUS05900P

UTILITY PATENT APPLICATION

Attorney Docket No

FAIENI AFFEICATION	First Inventor Nevin R. Lassila			
TRANSMITTAL	Title Acetylenic Diol Ethylene Oxide/Propylene Oxide			
(Only for new nonprovisional applications under 37 CFR 1.53(b))	Express Mail Label No. EL685721648US			
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility petent application contents.	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231			
Fee Transmittal Form (e.g., PTO/SB/17)	7. CD-ROM or CD-R in duplicate; large table or			
2. Applicant claims small entity status. See 37 CFR 1.27.	Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)			
3. X Specification [Total Pages 44] }	a. Computer Readable Form (CRF)			
- Cross Reference to Related Applications	 b. Specification Sequence Listing on: i. D CD-ROM or CD-R (2 copies); or 			
Statement Regarding Fed sponsored R & D Reference to sequence listing, a table,	ii. D paper			
or a computer program listing appendix - Background of the Invention	c. Statements verifying identity of above coples			
- Brief Summary of the Invention	ACCOMPANYING APPLICATION PARTS			
Brief Description of the Drawings (if filed) Detailed Description	9. X Assignment Papers (cover sheet & document(s))			
- Claim(s)	37 CFR 3.73(b) Statement X Power of			
- Abstract of the Disclosure	(when there is an assignee) Attorney			
4. Drawing(s) (35 U.S.C. 113) [Total Sheets]	11. English Translation Document (if applicable)			
5. Oath or Declaration [Total Pages 2]	12. Information Disclosure Statement (IDS)/PTO-1449 Citations			
a. X Newly executed (original or copy) Copy from a prior application (37 CFR 1.63 (d))	13. Preliminary Amendment			
b. (for continuation/divisional with Box 17 completed)	14. X Return Receipt Postcard (MPEP 503) (Should be specifically itemized)			
i. DELETION OF INVENTOR(S)	15. Critiled Copy of Priority Document(s) (if foreign priority is claimed)			
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR	16. Other:			
1.63(d)(2) and 1.33(b). 6. Application Data Sheet. See 37 CFR 1.76	Olia.			
17. If a CONTINUING APPLICATION, check appropriate box, and sup	ply the requisite information below and in a preliminary amendment.			
or in an Application Data Sheet under 37 CFR 1.76:	09 304 607			
Continuation Divisional Continuation-in-part (CIP) Prior application information: Examiner Edward Cain	Group / Art Unit: 1714			
	Group / Art Unit:			
For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hareby incorporated by reference. The incorporation <u>can only</u> be relied upon when a portion has been inadvertently omitted from the submitted application parts.				
18. CORRESPOND				
Customer Number or Bar Code Label	or Correspondence address below			
Name	IIII III			
23543				
Address	incare, mic.			
City	State Zip Code			
Country Te	lephone Fax			
Name (Printl Type) Michael Leach	Registration No. (Attorney/Agent) 27,349			
Signature Military Town	Date 11 Oct 201			

Burden Hour Statement: This form is "strimated to take 0.2 North to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patient and Trademark Office, Washington, DC 20231. Do NOT SEND FESS OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patients, Sox Pasint Application, Washington, DC 20231.

PTC/SB/17 (10-01)
Approved for use through 10/31/20/2 OMB 0651-03/3
U.S. Patent end Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a valid OMR

FEE TRANSMITTAL for FY 2002

Petent fees ere subject to ennual revision.

TOTAL AMOUNT OF PAYMENT	(\$)	776.00

Complete if Known		
Application Number		
Filing Date		
First Named Inventor		
Examiner Name		
Group Art Unit		
Attornov Docket No.	113DLIS05000D	

METHOD OF PATINENT	FEE CALCULATION (CONTINUED)	
1. X The Commissioner is hereby authorized to charge	3. ADDITIONAL FEES	
indicated fees and credit any overpayments to: Deposit	Large Small	
Account Number 01-0493	Entity Entity Fee Fee Fee Fee Fee Description	Fee Paid
Denosit	Code (\$) Code (\$)	100.000
Account Neme Air Products and Chemicals, Inc.	105 130 205 65 Surcherge - late filing fee or oath	
Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17	127 50 227 25 Surcherge - late provisional filing fee or cover sheet	
Applicant claims small entity status.	139 130 139 130 Non-English specification	
See 37 CFR 1.27	147 2,520 147 2,520 For filing a request for ex parte reexamination	
2. Payment Enclosed: Check Credit card Money Other	112 920* 112 920* Requesting publication of SIR prior to Examiner action	
FEE CALCULATION	113 1,840° 113 1,840° Requesting publication of SIR after Examiner action	
1. BASIC FILING FEE	115 110 215 55 Extension for reply within first month	
Large Entity Small Entity	116 400 216 200 Extension for reply within second month	
Fee Fee Fee Fee Description Code (\$) Code (\$) Fee Paid	117 920 217 460 Extension for reply within third month	
101 740 201 370 Utility filing fee 740	118 1,440 218 720 Extension for reply within fourth month	
106 330 206 165 Design filing fee	128 1,960 228 980 Extension for reply within fifth month	
107 510 207 255 Plant filing fee	119 320 219 160 Notice of Appeal	
108 740 208 370 Reissue filing fee	120 320 220 160 Filing a brief in support of an appeal	
114 160 214 80 Provisional filing fee	121 280 221 140 Request for oral hearing	
SUBTOTAL (1) (\$) 740	138 1,510 138 1,510 Petition to institute a public use proceeding	
2. EXTRA CLAIM FEES	140 110 240 55 Petition to revive - unavoideble	
Fee from	141 1,280 241 640 Petition to revive - unintentional	
Extra Claims below Fee Paid Total Claims 22 -20* = 2 x 18 = 36	142 1,280 242 640 Utility issue fee (or reissue) 143 460 243 230 Design issue fee	
Independent 3 3 3 7 7 0 V 84	144 620 244 310 Plant issue fee	
Claims Multiple Dependent	122 130 122 130 Pelitions to the Commissioner	
	123 50 123 50 Processing fee under 37 CFR 1.17(g)	
Large Entity Smell Entity	126 180 126 180 Submission of Information Disclosure Stmt	
Fee Fee Fee Fee Fee Description Code (\$) Code (\$) 103 18 203 9 Claims in excess of 20	581 40 581 40 Recording each patent assignment per property (times number of properties)	
102 84 202 42 Independent claims in excess of 3	146 740 246 370 Filing a submission after final rejection (37 CFR § 1.129(a))	
104 280 204 140 Multiple dependent claim, if not peid 109 84 209 42 ** Reissue independent claims over original patent	149 740 249 370 For each additionel invention to be examined (37 CFR § 1.129(b))	
110 18 210 9 ** Reissue dalms in excess of 20	179 740 279 370 Request for Continued Examination (RCE)	
and over original patent	169 900 169 900 Request for expedited examination of a design epptication	
SUBTOTAL (2) (\$) 36	Other fee (specify)	
**or number previously paid, if greeter; For Reissues, see ebove	*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$)	0

SUBMITTED BY Complete (if applicable) 610-481-8519 Name (Print/Type) Michael Leach 27,349 Signature WARNING: Information on this form may become public. Credit card inf mation sh uid not

be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to teke 0.2 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chier Information Officer, U.S. Petent and Tradament, Office, washington, DC 20231. DO NOT SEND FEEC SO COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Patients, Washington, DC 20231.